Merck touts promising ADC sacituzumab tirumotecan as potential cornerstone therapy at ASCO
Merck highlighted a new antibody-drug conjugate, sacituzumab tirumotecan (sac-TMT), licensed from Chinese biotech Kelun-Biotech, at the ASCO meeting.
The company said early clinical data have given it confidence to launch an extensive Phase 3 program that now includes 17 studies across multiple tumor types.
Results presented showed that, after a median follow-up of about 10.5 months, the combination of sac-TMT with Keytruda produced encouraging outcomes, putting the drug on investors' radar.
Merck views sac-TMT as a potential "cornerstone" ADC that could help offset the upcoming loss of exclusivity for its blockbuster immunotherapy Keytruda.
This writeup was produced by pharmadog from original reporting by BioPharma Dive.
Original headline: “At ASCO, Merck makes case for a ‘cornerstone’ cancer drug”
read at BioPharma Dive ↗
comments(0)
5-min edit window · permanent after that